

UNIVERSIDADE ESTADUAL PAULISTA - UNESP
Instituto de Biociências de Botucatu
PROGRAMA DE PÓS-GRADUAÇÃO EM FARMACOLOGIA E
BIOTECNOLOGIA (PPG-FARMATEC)

**Título: Distúrbios na motilidade gastrintestinal
associados a alterações morfológicas de neurônios
entéricos em modelos experimentais de *Diabetes
mellitus***

Juliana Fernandes de Matos

Orientador: **Prof. Dr. José Ricardo de Arruda Miranda**

Coorientadora: **Prof. Dra. Madileine Francely Américo**

Tese apresentada ao Instituto de
Biociências, Universidade Estadual
Paulista “Júlio de Mesquita Filho”,
Campus de Botucatu para obtenção
do título de Doutora no Programa de
Pós-Graduação em Farmacologia e
Biotecnologia, Área de
concentração *Biologia Celular
Estrutural e Funcional*.

**Botucatu
2019**

Juliana Fernandes de Matos

Distúrbios na motilidade gastrointestinal associados a alterações morfométricas de neurônios entéricos em modelos experimentais de *Diabetes mellitus*

Orientador: **Prof. Dr. José Ricardo de Arruda Miranda**

Coorientadora: **Prof. Dra. Madileine Francely Américo**

Tese apresentada ao Instituto de Biociências, Universidade Estadual Paulista “Júlio de Mesquita Filho”, Campus de Botucatu para obtenção do título de Doutora no Programa de Pós-Graduação em Farmacologia e Biotecnologia, Área de concentração *Biologia Celular Estrutural e Funcional*.

FICHA CATALOGRÁFICA ELABORADA PELA SEÇÃO TÊC. AQUIS. TRATAMENTO DA INFORM.
DIVISÃO TÉCNICA DE BIBLIOTECA E DOCUMENTAÇÃO - CÂMPUS DE BOTUCATU - UNESP

BIBLIOTECÁRIA RESPONSÁVEL: LUCIANA PIZZANI-CRB 8/6772

Matos, Juliana Fernandes de.

Distúrbios na motilidade gastrintestinal associados a alterações morfológicas de neurônios entéricos em modelos experimentais de *Diabetes mellitus* / Juliana Fernandes de Matos. - Botucatu, 2019

Tese (doutorado) - Universidade Estadual Paulista "Júlio de Mesquita Filho", Instituto de Biociências de Botucatu

Orientador: José Ricardo de Arruda Miranda

Coorientador: Madileine Francely Américo

Capes: 21000000

1. Biosusceptometria de Corrente Alternada. 2. Estômago. 3. Sistema gastrointestinal - Motilidade. 4. Neurônios. 5. Ratos.

Palavras-chave: Biosusceptometria AC; Estômago; Motilidade; Neurônios; Ratos.

Dedicatória

Ao Professor Doutor José Ricardo de Arruda Miranda, por me orientar e compartilhar os seus conhecimentos científicos;

À Professora Doutora Madileine francely Americo, por me auxiliar e me ensinar a fazer pesquisa e desenvolver experimentos;

À Professora Doutora Patrícia Castelucci, por colaborações essenciais para o desenvolvimento do trabalho;

À Professora Doutora Maeli Dal Pai, pelo apoio e colaboração essencial em diversas partes do trabalho;

Aos amigos do laboratório de Biomagnetismo, pelo suporte e companheirismo em todos esses anos;

Minha profunda gratidão a todos que, direta ou indiretamente, ajudaram na elaboração deste trabalho.

"A tarefa essencial do professor é despertar a alegria de trabalhar e de conhecer."

(Albert Einstein)

Agradecimientos

Agradeço a Deus por me conceder muita fé e perseverança para continuar lutando, vencendo todos os obstáculos e ter chegado até onde cheguei.

Agradeço ao apoio da minha família, sem essa base eu não seria a pessoa que sou hoje. Ao meu Pai, que sempre acreditou em mim, me apoiando e investindo na minha formação. A minha Mãe, que não está mais presente em minha vida, mas deve estar feliz por eu ter realizado um sonho. As minhas irmãs, que sempre me aconselharam e me guiaram para eu alcançar meus almejos. Ao meu companheiro Willians, que com muita paciência e carinho sempre esteve ao meu lado.

Agradeço a todos meus amigos que me acompanharam todos esses anos, me apoiando e dando todo o suporte que eu necessitava. Obrigada por todas as conversas, conselhos e companheirismo, a amizade de todos me fez crescer muito como pessoa.

Agradeço ao meu Professor, Prof. Dr. José Ricardo de Arruda Miranda, e aos meus colegas de laboratório, que me acolheram com muito carinho e que me passaram muito conhecimento.

Agradeço às agências de fomento CAPES e Fundação de Amparo à pesquisa (FAPESP processo nº 2015/05045-8), com o apoio financeiro concedido foi possível realizar o projeto proposto.

Obrigado a todas as pessoas que contribuíram para meu sucesso e para meu crescimento como pessoa. Sou o resultado da confiança e da força de cada um de vocês.

*“Por vezes sentimos que aquilo que fazemos não é senão uma gota de
água no mar. Mas o mar seria menor se lhe faltasse uma gota.”*
(Madre Teresa de Calcutá)

Financiamento

Bolsa CAPES de doutorado

Vigência da bolsa: 01/03/2015 à 01/10/2015.



Bolsa FAPESP de doutorado

Agradecimento à agência de fomento Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), nº do processo 2015/05045-8

Vigência da bolsa: 01/11/2015 à 01/03/2019 (36 meses regular + 4 meses de renovação).



Resumo

O estado hiperglicêmico está relacionado com alterações fisiológicas em todo o organismo no diabetes. É conhecido a recorrência de distúrbios gastrintestinais em indivíduos diabéticos. Estudos sobre alterações da motilidade gastrintestinal em diabéticos mostram danos em neurônios entéricos e na parede gástrica. Há uma lacuna no conhecimento sobre a relação entre níveis glicêmicos, motilidade gastrintestinal e neurônios entéricos. Portanto o objetivo foi analisar a atividade de contração, esvaziamento gástrico e trânsito oro-cecal em ratos com modelos de diabetes grave e moderado e avaliar a integridade da parede gástrica e dos neurônios entéricos. Os animais foram induzidos ao diabetes com Streptozotocin (STZ) (diabetes moderado: 100mg/kg; glicemia de jejum 6,6-16,5 mmol/L) e (diabetes grave: 50mg/kg glicemia de jejum > 16,5mmol/L). A Biosusceptometria AC (BAC) aferiu a contratilidade gástrica, quantificados por frequência e meia-largura da banda em ciclos por minuto. Assim como o esvaziamento gástrico (EG) e o trânsito oro-cecal (TOC), analisados por tempo médio de EG e tempo médio de chegada ao ceco, respectivamente. A atividade elétrica gástrica foi aferida por eletrogastrograma (EGG). A histologia da parede gástrica foi realizada por hematoxilina-eosina e mensurada a espessura da mucosa e das musculares longitudinal e circular, do corpo do estômago. Os neurônios colinérgicos (ChAT) e nitrérgicos (nNOS) do plexo mioentérico do corpo do estômago foram marcados por imuno-histoquímica, analisadas a densidade de neurônios por gânglio e perfil da área neural. Animais induzidos por STZ apresentaram glicemia de jejum elevada e perda de peso corporal. Ocorreu uma diminuição da frequência de contração e aumento da meia-largura da banda, para BAC e EGG, nos modelos de diabetes comparados ao controle. O esvaziamento gástrico e o trânsito oro-cecal se tornaram lentificados em relação ao controle. A camada muscular circular e mucosa apresentaram espessamento nos grupos diabéticos. Os neurônios ChAT e nNOS não apresentaram diferença na densidade de neurônios, mas a área neuronal diminuiu nos diabéticos. Em conclusão, alterações na motilidade parecem estar associadas a mudanças na parede gástrica e à diminuição da área neuronal de neurônios nitrérgicos e colinérgicos, que foram intensificados pela exposição prolongada a condições hiperglicêmicas, mesmo que moderadas no diabetes.

Palavras-chave: Biosusceptometria AC, Estômago, Motilidade, Neurônios entéricos, Ratos.

Abstract

The hyperglycemic state is related to physiological changes throughout the body in diabetes. Recurrence of gastrointestinal disorders in diabetic individuals is known. Studies on changes in gastrointestinal motility in diabetics show damage to enteric neurons and the gastric wall. Few are the knowledge about the relationship among glycemic levels, gastrointestinal motility and enteric neurons. Therefore, the aim was to analyze the activity of contraction, gastric emptying and oro-cecal transit in rats with mild and severe diabetes models and to evaluate the integrity of the gastric wall and the enteric neurons. The animals were diabetic with Streptozotocin (STZ) (moderate diabetes: 100mg/kg; fasting blood glucose 6.6-16.5 mmol/L) and (severe diabetes: 50mg/kg fasting blood glucose >16.5mmol/L). AC biosusceptometry (ACB) measured gastric contractility, quantified per frequency and half-band width in cycles per minute. As well as gastric emptying (EG) and oro-cecal transit, analyzed by mean time of EG and mean time of arrival to the cecum, respectively. Gastric electrical activity was measured by electrogastrogram (EGG). The histology of the gastric wall was performed by hematoxylin-eosin and measured the thickness of the mucosa and the longitudinal and circular muscles of the stomach body. The cholinergic (ChAT) and nitrenergic (nNOS) neurons of the myenteric plexus of the stomach body were marked by immunohistochemistry, the density of neurons per ganglion and neural area profile were analyzed. STZ-induced animals had elevated fasting blood glucose and loss of body weight. There was a decrease in the contraction frequency and increase of the band half-width, for BAC and EGG, in the diabetes models compared to control. Gastric emptying and oro-cecal transit became slowed in relation to control. The circular muscular layer and mucosa presented thickening in the diabetic groups. ChAT and nNOS neurons showed no difference in neuron density, but neuronal area decreased in diabetics. In conclusion, alterations in motility seems to be associated with changes in the gastric wall and the decrease in the neuronal area of nitrenergic and cholinergic neurons that were intensified by long term exposure to hyperglycemic conditions, even that moderate in the diabetes.

Keywords: Biosusceptometry AC, Stomach, Motility, Enteric neurons, Rats.

Lista de Abreviaturas

DM - *Diabetes mellitus*

DM1 - *Diabetes mellitus* tipo 1

DM2 - *Diabetes mellitus* tipo 2

DM1W - *Diabetes mellitus* 1 semana

DM1M - *Diabetes mellitus* 1 Mês

DM mild - *Diabetes mellitus* moderado/mild

CT - Controle

BAC/ACB - Biousceptometria de Corrente Alternada

EGG - Eletrogastrograma

STZ - Streptozotocin

ChAT – Neurotransmissor Acetiltransferase colina

NOS – Enzima óxido nítrico sintetase

nNOS – Neurônio óxido nítrico sintetase

NO - Óxido nítrico

HuC/D - Anticorpo pan-neuronal

DAPI - 4,6 diamino 2-phenylindole dihydrochride

TRIS- hidroximetil aminometano

EDTA - ácido etilenodiaminotetracético

PBS - Tampão fosfato salino

TGI/GIT - Trato gastrintestinal

CPM - Ciclos por minuto

AG/GA - Atividade gástrica

MGET - Tempo médio de esvaziamento gástrico

EG/GE - Esvaziamento gástrico

OCT - Trânsito oro-cecal

MCAT - Tempo médio de chegada ao ceco

HE - Hematoxilina e Eosina

SNE/ENS - Sistema nervoso entérico

SNC/CNS - Sistema nervoso central

FFT - Transformada rápida de Fourier

AUC - Área sob a curva

AGEs - Prdutos finais da glicação avançada

ROS/EROs - Espécies reativas do oxigênio

Sumário

1. Introdução	1
2. Capítulo 1	8
INTRODUCTION	12
MATERIALS AND METHODS.....	14
Animal models	14
Induction of Diabetes mellitus models.....	14
Gastric activity (GA).....	15
Mean Gastric Emptying Time (MGET) and Mean Cecum Arrival Time (MCAT)	15
Histological analysis	16
Immunohistochemistry	16
Data analysis	17
Statistical analysis	18
RESULTS.....	18
Fasting blood glucose determination and body weight measurement	18
Gastric activity (GA).....	18
Mean Gastric Emptying Time (MGET) and Mean Cecum Arrival Time (MCAT)	19
Histological analysis	19
Immunohistochemistry	20
DISCUSSION	20
REFERENCES.....	25
3. Conclusões.....	38
4. Referências	40
5. Apêndice A	46
6. Apêndice B	48

Lista de Ilustrações

FIGURA 1 ANALYSIS OF GASTROINTESTINAL MOTILITY AND MORPHOMETRY OF THE STOMACH AND ENTERIC NEURONS OF DIABETIC AND CONTROL RATS	32
FIGURA 2 PROFILE OF GASTRIC MOTILITY SIGNALS MEASURED BY BAC AND ANALYZED BY MATLAB.....	33
FIGURA 3 ANALYSIS OF THE MUSCULAR LAYERS OF THE STOMACH OF GROUPS USING HE STAINING	34
FIGURA 4 COLOCALIZATION OF HUC/D IMMUNOREACTIVITY WITH CHAT IMMUNOREACTIVITY IN NEURONS OF THE STOMACH MYENTERIC PLEXUS IN THE DIABETIC AND CONTROL ANIMALS	35
FIGURA 5 COLOCALIZATION OF HUC/D IMMUNOREACTIVITY WITH NOS IMMUNOREACTIVITY IN NEURONS OF THE STOMACH MYENTERIC PLEXUS IN THE DIABETIC AND CONTROL ANIMALS	36

Introdução

1. Introdução

A epidemia global de diabetes afeta atualmente mais de 440 milhões de pessoas no mundo (CHAN, 2014; MA, 2018). O *Diabetes mellitus* (DM) compreende um grupo de distúrbios metabólicos caracterizados por hiperglicemia crônica resultante de defeitos na ação da insulina e/ou na sua secreção (DORSEY; BECKER; AL., 2018; RIDDLE et al., 2018). Existem principalmente 2 tipos de DM: tipo 1 e o 2. O DM1 está relacionado à destruição de células beta pancreáticas, usualmente levando a uma dependência absoluta de insulina. Enquanto o DM2 decorre de um defeito progressivo da secreção de insulina levando a uma resistência insulínica (RIDDLE et al., 2018). Algumas formas de DM1 não têm etiologias conhecidas, mas é definido que há pelo menos um marcador celular autoimune indicando a destruição de células beta pancreáticas. Os pacientes apresentam insulinopenia permanente e são propensos a cetoacidose (RIDDLE et al., 2018). Indivíduos com DM2 tem resistência à insulina e normalmente uma relativa deficiência desse hormônio, porém a maioria dos pacientes não necessita de tratamento com insulina para sobreviver. A etiologia do DM2 é desconhecida, mas sabe-se que o risco de a desenvolver aumenta com a obesidade, avanço da idade e a falta de atividade física (RIDDLE et al., 2018).

Em indivíduos saudáveis, a concentração de glicose plasmática é fortemente regulada e mantida dentro de uma faixa estreita (KELLEY et al., 1988). Em contrapartida, pacientes diabéticos são expostos a longos períodos de hiperglicemia e apresentam disfunções em todo o organismo (DORSEY; BECKER; AL., 2018).

Anormalidades na motilidade gástrica ocorrem em 30-50 % dos pacientes com longo histórico de diabetes (DE BLOCK et al., 2006; NILSSON, 1996). Estudos de frequência de sintomas gastrintestinais em pacientes com DM1 e DM2 mostraram que 68% apresentam pelo menos um sintoma (JEBBINK et al., 1994; SPÅNGÉUS et al., 1999). O DM1 afeta todo o trato gastrintestinal (TGI) e isso acarreta uma maior preocupação na investigação dessas alterações e na busca de uma melhora na qualidade de vida dos pacientes, visando reduzir a morbidade causada pelo diabetes. As alterações mais comuns encontradas no diabetes são no esvaziamento gástrico, como lentificação (MARD et al., 2016; SAMSOM et al., 1997; WOERLE et al., 2008) ou esvaziamento acelerado (BHARUCHA et al., 2015; CHOI et al., 2007; HAUSCHILDT et al., 2018). Presença de arritmias gástricas e anormalidade nas atividades motora e elétrica gástrica são reportadas em modelos experimentais de diabetes a longo termo (HAUSCHILDT et al., 2018; MARQUES et al., 2014).

Indivíduos com DM1 apresentam uma retenção gástrica significativa dos conteúdos ingeridos em resposta à hiperglicemia quando comparados a indivíduos saudáveis, sugerindo uma adaptação inadequada ao aumento da glicemia (MARATHE et al., 2013). Consequentemente, com o esvaziamento gástrico atrasado há uma dificuldade em manter o controle glicêmico, sendo esse um mecanismo de retroalimentação (WOERLE et al., 2008). O retardo no esvaziamento gástrico em momentos de hiperglicemia é uma resposta fisiológica pós-prandial, mecanismo este que auxilia na absorção dos nutrientes ingeridos. Porém em pacientes com DM1, esse mecanismo favorece a manutenção de altos índices glicêmicos e distúrbios na motilidade gastrointestinal (WOERLE et al., 2008).

Há trabalhos que enfatizam a importância do controle glicêmico no diabetes, e enfatiza as alterações provocadas pela glicemia na motilidade gastrointestinal (MARATHE et al., 2013; SOGABE et al., 2005). Um estudo ressalta que a hiperglicemia induz um relaxamento na região fúndica do estômago causando um fluxo pilórico retrógrado, que por sua vez, pode levar a uma retenção do bolo alimentar (EBERT, 2005).

Com relação aos indivíduos com DM2 os estudos são inconclusivos, em razão de diferenças nas metodologias adotadas e pouco controle das variáveis ambientais sobre o esvaziamento gástrico. Foi demonstrado que indivíduos com DM2 sem controle glicêmico quando tratados com insulina, não apresentaram diferença no esvaziamento gástrico, e que há pacientes com DM2 que tem esvaziamento gástrico acelerado e outros retardado (BHARUCHA et al., 2015).

A motilidade gastrintestinal é a contração e relaxamento do músculo liso necessário para transportar e processar os alimentos, sob estrito controle (CUMMINGS; OVERDUIN, 2007; JOHNSON, 2014). A contração do estômago é necessária para triturar o alimento, misturar com o suco gástrico e propelir em direção ao piloro. O controle da frequência e amplitude dessas contrações são essenciais para absorção dos nutrientes (JANSSEN et al., 2011). Assim como o esvaziamento gástrico é controlado por peptídeos gastrintestinais (GLP-1, GIP, VIP), pela taxa glicêmica, insulina, composição do bolo alimentar e controle neural. Todos esses controles são necessário para regular a taxa de esvaziamento e promover a absorção correta pelo intestino. Alterações em qualquer uma dessas vias desencadeia diversos distúrbios gastrintestinais, como dores e desconfortos abdominais (BOECKXSTAENS et al., 2016; CAMILLERI; BROWN; MALAGELADA, 1986; CUMMINGS; OVERDUIN, 2007;

MARATHE et al., 2013; WU et al., 2013).

O diabetes afeta o TGI comprometendo a motilidade, além de possivelmente alterar a parede gastrintestinal, assim como os neurônios entéricos responsáveis pelo controle das funções do TGI. A inter-relação entre biomecânica gastrintestinal e neurônios entéricos é relevante e deve ser melhor esclarecida. Essas alterações morfofuncionais são fatores que podem contribuir com a dor abdominal, saciedade precoce, náuseas, vômitos, e constipação em pacientes com DM (EBERT, 2005; FURNESS, 2012; MARATHE et al., 2013; ZHAO; NAKAGUCHI; GREGERSEN, 2009).

O sistema nervoso entérico (SNE) está presente em todo o TGI e é responsável por regular funções motoras, sensoriais e secretoras, além de integrar e ser modulado pela sinalização do sistema nervoso central (SNC) e periférico (FURNESS, 2000). É dividido em plexo submucoso que está presente na camada submucosa e apresenta funções secretoras. O plexo mioentérico está presente entre as camadas musculares circular e longitudinal, e tem funções sobre a motilidade do TGI. Os principais neurônios envolvidos no controle da motilidade são os excitatórios colina acetiltransferase (ChAT) e os inibitórios óxido nítrico sintetase (nNOS) (FURNESS, 2012).

A neuropatia diabética é um evento presente em pacientes com longo histórico de diabetes e pode estar correlacionada com gastroparesia e distúrbios gastrintestinais (CAMILLERI, 2007; CAMILLERI; BHARUCHA; FARRUGIA, 2011; CHANDRASEKHARAN; SRINIVASAN, 2007; NESHATIAN; GIBBONS; FARRUGIA, 2015). A perda de células de Cajal e diminuição do neurotransmissor óxido nítrico (NO) podem estar diretamente relacionados com disfunções na motilidade gástrica nesse tipo de pacientes diabéticos (CELLEK et

al., 2004; DU et al., 2009; WANG et al., 2009; WATKINS et al., 2000; WOOD, 2016). Trabalhos evidenciam fases da degeneração neuronal em indivíduos diabéticos, apresentando eventos reversíveis com o controle glicêmico, em momentos precoces da doença (CELLEK et al., 2004; CELLEK; FOXWELL; MONCADA, 2003). Isso evidencia a necessidade de um diagnóstico preciso e precoce para se evitar danos irreversíveis aos indivíduos com DM.

Além disso, indivíduos com DM1 são mais susceptíveis a lesões gástricas malignas, primárias de gastrite autoimune, presente em 15-20% desses pacientes (DE BLOCK et al., 2003). Ou seja, quanto mais conhecimento sobre os mecanismos desses distúrbios gastrintestinais mais rápido seria o diagnóstico, aperfeiçoando os esquemas terapêuticos e a qualidade de vida de indivíduos diabéticos.

Como ferramenta experimental, utilizam-se modelos animais portadores de diabetes para um melhor entendimento da fisiopatologia dessa síndrome. Mimetizando a hiperglicemia do DM1, há o modelo experimental de diabetes grave (glicemia > 300mg/dL), induzida por uma dose de Streptozotocin-STZ (droga com efeito citotóxico sobre as células beta pancreáticas) intraperitoneal na vida adulta (FREGONESI et al., 2001). Para mimetizar a glicemia do DM2, utiliza-se o modelo experimental de diabetes moderado (glicemia entre 120 e 300mg/dL), induzida por administração subcutânea de STZ no período neonatal (DAMASCENO et al., 2013, 2014; I.L. et al., 2010).

A Biosusceptometria de Corrente Alternada (BAC) é uma técnica simples, barata e sensível, reproduzível em diversas áreas da pesquisa. Com a utilização dessa técnica é possível registrar a atividade mecânica e funcional de órgãos contráteis. Essa técnica já foi validada para várias áreas, como para avaliação

do esvaziamento gástrico e trânsito oro-cecal em ratos(QUINI et al., 2012). Estudos *in vivo* e *in vitro* validaram a BAC como uma técnica biomagnética capaz de aferir atividade de contração gástrica (AMÉRICO et al., 2010). Em modelo de diabetes a longo tempo induzido por Aloxana, os sinais de contratilidade e esvaziamento gastrintestinal, aferidos por BAC, estavam comprometidos (MARQUES et al., 2014). Estudos recentes com a BAC, em modelos de hiperglicemia moderada a longo tempo, revelam distúrbios gástricos como esvaziamento acelerado e amplitudes da contração gástrica mais vigorosas (HAUSCHILDT et al., 2018).

Em estudos que analisam características motoras do TGI, a aquisição da atividade elétrica é fundamental para o entendimento da eletrofisiologia do tecido estudado. O eletrogastrograma (EGG) é uma técnica bastante simples, minimamente invasiva e utilizada principalmente em pesquisas da atividade elétrica gástrica. O entendimento das funções motoras e elétricas do TGI são essenciais nas pesquisas sobre comorbidades relacionadas aos distúrbios gastrintestinais (CHEN et al., 1996).

A relação entre distúrbios gastrintestinais no diabetes e o tempo de instalação das condições hiperglicêmicas ainda é pouco compreendido. Além disto, uma avaliação das atividades elétricas, mecânicas e funcionais do TGI contribuirão fortemente para um melhor entendimento de mecanismos deletérios da instalação de doenças metabólicas. Portanto o objetivo foi analisar a atividade de contração, esvaziamento gástrico e trânsito oro-cecal em ratos com modelos de diabetes grave e moderado e avaliar a integridade da parede gástrica e dos neurônios entéricos.

Capítulo 1

2. Capítulo 1

Manuscript Type: ORIGINAL ARTICLE

Basic Study

Disorders in gastrointestinal motility associated with morphometric alterations of enteric neurons in experimental models of *Diabetes mellitus*

Matos J F *et al.* Changes in gastrointestinal motility in diabetic rats.

Juliana Fernandes Matos, Madileine Francely Américo, Patrícia Castelucci, Maeli Dal-Pai, José Ricardo Arruda Miranda.

Juliana Fernandes Matos, Jose Ricardo Arruda Miranda, Department of Physics and Biophysics, Paulista State University – UNESP, Botucatu/SP, 18618-970, Brazil

Madileine Francely Américo, Institute of Biological Sciences and Health, Federal University of Mato Grosso - UFMT, Barra do Garças/MT, 78600-000, Brazil

Patrícia Castelluci, Department of Anatomy, University of São Paulo-USP, São Paulo/SP, 05508-900, Brazil

Maeli Dal-Pai, Department of Morphology, Paulista State University – UNESP, Botucatu/SP, 18618-970, Brazil

ORCID number: Juliana Fernandes de Matos (0000-0002-9366-1988); Madileine Francely Américo (0000-0001-8474-3765); Patrícia Castelucci (0000-0002-7475-5962); Maeli Dal Pai (0000-0001-7269-9197); José Ricardo de Arruda Miranda (0000-0001-(0000-0002-8306-8056)).

Author Contribution: Matos JF and Miranda JRA designed the study; Matos JF performed experiments, analyzed the data; Matos JF and Américo MF wrote the

paper; Américo MF, Castelucci P, Dal-Pai M and Miranda JRA revised critically the paper. The final version of manuscript was read and approved by all authors.

Supportive foundation: Partially supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) n. 2015/05045-8 and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).

Institutional animal care and use committee statement: All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of the Bioscience Institute/UNESP Ethics Committee on Use of Animals (CEUA Process 752).

Conflict-of-interest statement: No conflict of interest

Correspondence to Juliana Fernandes de Matos, MSc, Doctoral Student, Institute of Biosciences, Paulista State University – UNESP, Street Prof. Dr. Antonio Celso Wagner Zanin, Botucatu/SP, 18618-970, Brazil

Juliana.matos@unesp.br

Telephone +55-14-38800285

Abstract

BACKGROUND

The hyperglycemic state is related to physiological changes throughout the body in diabetes. Recurrence of gastrointestinal disorders in diabetic individuals is known. Studies on changes in gastrointestinal motility in diabetics show damage to enteric neurons and the gastric wall. Few are the knowledge about the relationship among glycemic levels, gastrointestinal motility and enteric neurons.

AIM

To analyze the activity of contraction, gastric emptying and oro-cecal transit in rats with mild and severe diabetes models and to evaluate the integrity of the gastric wall and the enteric neurons.

METHODS

The animals were diabetic with Streptozotocin (STZ) (moderate diabetes: 100mg/kg; fasting blood glucose 6.6-16.5 mmol/L) and (severe diabetes: 50mg/kg fasting blood glucose >16.5mmol/L). AC biosusceptometry (ACB) measured gastric contractility, quantified per frequency and half-band width in cycles per minute. As well as gastric emptying (EG) and oro-cecal transit, analyzed by mean time of EG and mean time of arrival to the cecum, respectively. Gastric electrical activity was measured by electrogastrogram (EGG). The histology of the gastric wall was performed by hematoxylin-eosin and measured the thickness of the mucosa and the longitudinal and circular muscles of the stomach body. The cholinergic (ChAT) and nitrergic (nNOS) neurons of the myenteric plexus of the stomach body were marked by immunohistochemistry, the density of neurons per ganglion and neural area profile were analyzed.

RESULTS

STZ-induced animals had elevated fasting blood glucose and loss of body weight. There was a decrease in the contraction frequency and increase of the band half-width, for BAC and EGG, in the diabetes models compared to control. Gastric emptying and oro-cecal transit became slowed in relation to control. The circular muscular layer and mucosa presented thickening in the diabetic groups.

ChAT and nNOS neurons showed no difference in neuron density, but neuronal area decreased in diabetics.

CONCLUSIONS

In conclusion, alterations in motility seems to be associated with changes in the gastric wall and the decrease in the neuronal area of nitrergic and cholinergic neurons that were intensified by long term exposure to hyperglycemic conditions, even that moderate in the diabetes.

Key Words

Gastrointestinal motility, Gastric wall, Enteric neurons, Hyperglycemia, Experimental diabetes.

INTRODUCTION

The global epidemic of *Diabetes mellitus* (DM) currently affects more than 440 million people worldwide^[1,2]. It is known that the hyperglycemic state is related to physiological changes throughout the body in diabetes.

There is a high recurrence of gastrointestinal (GI) disorders in diabetic individuals. Abnormalities in gastric motility occur in 30-50% of patients with a long history of diabetes^[3,4]. Studies of the frequency of gastrointestinal symptoms in patients with type 1 DM (DM1) and type 2 DM (DM2) showed that 68% had at least one symptom^[5,6]. DM1 affects the entire gastrointestinal tract (GIT), and this leads to more significant concern in the investigation of these alterations and the search for an improvement in patient's quality of life. The most common changes found in diabetes are in gastric emptyings, such as slowing down^[7-9] or accelerated emptying^[10-12]. Presence of gastric arrhythmias and abnormalities in motor and gastric electrical activities are reported in experimental models of long-term diabetes^[12,13].

Individuals with DM1 present significant gastric retention of the ingested contents in response to hyperglycemia when compared to healthy individuals, suggesting an inadequate adaptation to the increase of glycemia^[14]. Consequently, with delayed gastric emptying, there is a difficulty in maintaining glycemic control, which is a feedback mechanism^[9]. The delay in gastric emptying at times of hyperglycemia is a postprandial physiological response, a mechanism that helps in the absorption of ingested nutrients. However, in patients with DM1, this mechanism favors the maintenance of high glycemic indexes and disturbances in gastrointestinal motility^[9].

Diabetes affects GIT by compromising motility, possibly altering the gastrointestinal wall, as well as the enteric neurons responsible for the control of GIT functions. The interrelationship between gastrointestinal biomechanics and enteric neurons is relevant and should be further clarified. These morphofunctional changes are factors that may contribute to abdominal pain, early satiety, nausea, vomiting, and constipation in patients with DM^[14-17].

The enteric nervous system (ENS) is present throughout the GIT and is responsible for regulating motor, sensory and secretory functions, as well as integrating and being modulated by the central nervous system (CNS) and peripheral^[18]. It is divided into a submucosal plexus that is present in the submucosal layer and presents secretory functions. The myenteric plexus is present between the circular and longitudinal muscular layers and has functions on the motility of the GIT. The principal neurons involved in motile control are the excitatory choline acetyltransferase (ChAT) and the inhibitory nitric oxide synthetase (nNOS)^[16].

Diabetic neuropathy is an event present in patients with a long history of diabetes and may be correlated with gastroparesis and gastrointestinal disorders^[19-22]. The loss of Cajal cells and decreased neurotransmitter nitric oxide (NO) may be directly related to dysfunctions in gastric motility in this type of diabetic patients^[23-27]. Studies evidenced phases of neuronal degeneration in diabetic subjects, presenting reversible events with glycemic control, at early stages of the disease^[25,28]. This evidences the need for an accurate and early diagnosis to avoid irreversible damage to individuals with DM. That is, the more knowledge about the mechanisms of these gastrointestinal disorders, the faster the diagnosis, improving the therapeutic schemes and the quality of life of diabetic individuals.

There are many contradictions about the application of different experimental models of diabetes and their findings on gastrointestinal motility. In animal models of long-term diabetes induced by *Aloxan*, gastric contractility presented arrhythmias, and gastrointestinal emptying became slow^[13]. Recent studies in models of mild hyperglycemia over a long time reveal gastric disorders such as accelerated emptying and more vigorous gastric contraction amplitudes^[12].

The relationship between gastrointestinal disorders in diabetes and the time of setting of hyperglycaemic conditions is still poorly understood. Also, a temporal evaluation of the electrical, mechanical and functional activities of GIT will actively contribute to a better understanding of deleterious mechanisms of the installation of metabolic diseases. Therefore, the aim was to analyze the activity of contraction, gastric emptying, and oro-cecal transit in rats with mild and severe diabetes models and to evaluate the integrity of the gastric wall and the enteric neurons.

MATERIALS AND METHODS

All the experiments were performed according to the protocol of animal ethics of the Institute of Biosciences of Botucatu (CEUA 752).

Animal models

Male Sprague-Dawley rats from the ANILAB Laboratory (Paulínea-SP/Brazil) with 90 days of age and 300-350 g were used. The animals were kept under controlled conditions of temperature (22 ± 2 ° C), humidity ($50 \pm 10\%$), and light/dark cycle (12h), with water and feed ad libitum. Before the experiments, the body weight determined. After completion of the experiments, the animals were killed with 5% Isoflurane (Cristália®) overdose followed by decapitation.

Induction of Diabetes mellitus models

- Control animals (CT, N=8 rats) received an intraperitoneal injection of vehicle and presented fasting blood glucose between 4.95-5.5 mmol/L.
- Mild diabetes (DM mild, N=12 rats) was induced on the first day of life of the animals by subcutaneous administration of Streptozotocin (STZ-SIGMA Chemical Company, St. Louis, MO) at a dose of 100 mg/kg body weight diluted in 0.1 mol/L of (pH 4.5)^[29-31]. The animals kept with the mother until weaning. In the adult phase (90 days of age) the fasting glucose was performed to confirm the diabetic state, using the glucometer (ACCU-CHEK Performa, Roche, Germany). The rats remained fasted overnight before collecting the blood sample, which was performed by retro-orbital puncture. The inclusion criterion established for the mild diabetic group consisted of rats that presented glycemic values between 6.6 and 16.5 mmol/L^[32]. This model resembles the hyperglycemic conditions of DM2.
- Severe diabetes-induced on the 90th day of life by intraperitoneal administration of STZ at the dose of 50 mg/kg body weight diluted in citrate buffer. The inclusion criterion established to compose the severe diabetic group consisted of rats that presented glycemic values higher than 16.5 mmol/L ^[29,33]. This model resembles the hyperglycemic conditions of DM1.

The animals were submitted to the experiments at two different times: one week (DM1W, N=12 rats) and one month (DM1M, N=12 rats) after induction [34].

Gastrointestinal experiments were performed in all animals in the adult phase (around 90 days of life).

Gastric activity (GA)

In all experiments using ACB, the rats were fed 2 g of ferromagnetic material used as a marker (0.5 g of powdered ferrite and 1.5 g of feed) after a 12 hour fast.

At the end of the feeding, gastric activity was measured by ACB (mechanical activity) and Electrogastrography (EGG-electrical activity), acquiring frequency of contractions of the stomach in cycles per minute (CPM). The animals were anesthetized with Isoflurane® (5% induction, 2% maintenance) and placed in dorsal decubitus for the acquisition of the records. The magnetic sensor positioned over the abdomen in the anatomical region of the stomach. Due to gastric contractions, the magnetic marker is moved away and approached, respectively, from the sensor. That movement generates an oscillation in the magnetic field, which is converted into a digital signal and recorded in real time by a multi-channel recorder (MP150 System; BIOPAC®, CA-United States). For the EGG acquisition, the bipolar arrangement of needle electrodes (the positive entry in the left hypochondrium, the negative one in the right hypochondrium) and the ground in the hind paw (0.35 x 12 mm Ethicon®), and connected to the electrical signal acquisition system (Biopac EGG150C). The records lasted for 30 min and were performed simultaneously with a rate of 20 Hz.

The signal irregularity was measured through the Half-bandwidth, extracted from the contraction frequency signals of ACB and EGG.

Mean Gastric Emptying Time (MGET) and Mean Cecum Arrival Time (MCAT)

At the end of the feeding, gastric emptying (EG) and oro-cecal transit (OCT) performed at two points: stomach and cecum (anatomical references)^[35]. Measurements of EG and OCT by ACB consist of assaying the amount of magnetic

material in the stomach and cecum with the magnetic sensor after ingestion of the marked feed for 6 hours (measurements every 15 min) in an awake animal. Two parameters, Mean Gastric Emptying Time (MGET) and Mean Cecum Arrival Time (MCAT) was obtained^[35,36].

Histological analysis

After the experiments, the animals were anesthetized and killed; the stomach was collected and opened by the larger mesenteric border. A portion of the body region of the stomach was collected. The samples washed with Phosphate Buffered saline (PBS) and fixed with 4% Paraformaldehyde in 0.1M Phosphate Buffer overnight. Then the samples were dehydrated in a graduated ethanol series (70, 80, 90 and 100%) and embedded in paraffin. The materials were slice perpendicular to the sample, with 0.5µm thickness using microtome. Sections were rehydrated in 100, 90, 80 and 70% ethanol, followed by a wash in tap water and stained with Hematoxylin and Eosin (HE). The images were obtained using the LEICA DM LS microscope with a 10x magnification, and image analysis performed by *Image-Pro Plus software*.

Immunohistochemistry

Immunohistochemistry performed on the histological sections of the stomach body of all groups. The slides were dewaxed with xylol washes and hydrated with graduated ethanol series (100, 90, 80 and 70%). Antigen retrieval was then performed to expose the epitopes and prepare for the immunohistochemical labeling reaction. For antigen retrieval, the slides were immersed in TRIS-EDTA pH 9.0 buffers (Labsynth Ltda) and placed in a 95 ° C water bath for 45 min. After the slides cooled to room temperature, the sections incubated in 10% normal horse serum in PBS containing 1.5% Triton X-100 for 45 min at room temperature. Double labeling was performed using the nNOS (host-sheep, dilution 1: 2000, Millipore) antiserum combinations with pan-neuronal HuC/D (host-mouse, dilution 1: 200, Molecular Probers) and ChAT-goat, 1: 200 dilution, Chemicon) with HuC/D. After incubation in primary antisera for one hour, the sections were washed three times

for 10 min in PBS and incubated in the respective secondary antibodies (Donkey anti-sheep IgG 488 1: 400 and Donkey anti-mouse IgG 594 1: 200; Molecular Probes). The sections were washed three times for 10 min in PBS and incubated for 5 min in 4,6-diamidino-2-phenylindole dihydrochloride (DAPI) to label all nuclei. After the last wash in PBS, the slides mounted on 0.5 M sodium carbonate buffered glycerol. The slides were examined using epifluorescence from the Nikon 80i microscope, and the images were captured using a digital camera, NIS Elements software (Nikon) and analyzed with *Image-Pro Plus software*.

Data analysis

For gastric contractility parameters, magnetic signals acquired in real time by Acknowledge® 4.0 software were analyzed by MatLab (Mathworks, Natick, MA, USA) by visual inspection. Subsequently, the use of Butterworth bi-directional bandpass filters by Fast Fourier Transform (FFT), with a cutoff frequency of 2-7 CPM. The highest peak frequency for each FFT determined as the dominant gastric frequency, and the lowest peak represented as signal noise. Half-bandwidth was quantized using the two points of the curve, where the intensity was half the maximum intensity (y-axis). In these two points, the corresponding frequencies (x-axis) indicate the aspect of the spectral distribution. It is performed a Gaussian adjustment of the spectral distribution to measure the half-width of the band at half height. This methodology was developed to quantify the irregularity of AG signals^[13].

For the analysis of gastric emptying and oro-cecal transit, we used the statistical moment, obtained by the temporal average normalized by the area under the curve (AUC) of gastric emptying and total transit. The MGET and MCAT (in minutes) characterized by the amount of test meal emptied at a time t.

For the morphometry of the muscular layers (longitudinal and circular) and mucosa of the stomach body, it was performed ten measurements of the perimeter (μm) of each layer of all animals. In the Immunohistochemistry was calculate the number of neurons per ganglion. For each animal examined using each of the 3 markers, around ten ganglia were identified.

The number of neurons per ganglion was counted under 40X magnification. To calculate the neuronal profile area (μm^2) of the cell bodies (ChAT, nNOS e HuC/D), 50 neurons from all animals for each of the 3 markers were photographed. The measurements were performed using the Image-Pro Plus.

Statistical analysis

The variables normality evaluated by the Kolmogorov-Smirnov test. The parametric data were analyzed using Student's t-test. The Mann-Whitney test used in non-parametric data. Values of $p < 0.05$ were considered statistically significant. Data expressed as mean $\pm$ standard error.

RESULTS

Fasting blood glucose determination and body weight measurement

In the figure 2A, animals induced by STZ showed increased fast blood glucose (FBG) and body weight (BW) loss, with DM1W (FBG 18.03 ± 0.78 ; BW 288 ± 7.1 ; $P \leq 0.001$), DM1M (FBG 23.79 ± 1.58 ; BW 257.5 ± 10.77 ; $P \leq 0.001$) and DMmild (FBG 10.84 ± 0.71 , $P \leq 0.001$; BW 312 ± 8.85 , $P \leq 0.05$), all groups compared to CT.

Gastric activity (GA)

Figure 1 exemplifies the signals of contractility obtained from the groups studied. In that signals, it is possible to observe how the signal of the gastric activity of diabetic animals presents irregularities. Figure 2B shows the quantification in the frequency of gastric contraction and the half-bandwidth (CPM) measured by ACB and EGG. There is no significant difference between the frequencies of electrical (EGG) and mechanical activity (BAC) for the same animal. There is a decrease in the frequency of contraction of the diabetes models DM1W (ACB 3.85 ± 0.093 , $P \leq 0.001$; EGG 3.99 ± 0.11 , $P = 0.007$), DM1M (ACB 3.69 ± 0.10 , $P \leq 0.001$; EGG 3.61 ± 0.11 , $P \leq 0.001$) and DMmild (ACB 3.68 ± 0.17 , $P = 0.006$; EGG 3.94 ± 0.16 , $P = 0.006$) compared to CT (ACB 4.41 ± 0.074 ; EGG 4.43 ± 0.077).

There was no significant difference in the frequency of contraction (BAC and EGG) among the diabetes models. In figure 2B we have the quantification of the half-bandwidth. The signal from diabetic animals has a spectrum with greater dispersion, with DM1W (ACB 0.31 ± 0.021 , $P \leq 0.001$; EGG 0.33 ± 0.041 , $P \leq 0.001$), DM1M (ACB 0.37 ± 0.030 , $P = 0.001$; EGG 0.38 ± 0.040 , $P = 0.001$) and DMmild (ACB 0.59 ± 0.067 , $P \leq 0.001$; EGG 0.56 ± 0.067 , $P \leq 0.001$) compared to CT (ACB 0.14 ± 0.018 ; EGG 0.15 ± 0.021). There was a significant increase of half-bandwidth in DMmild compared to DM1W (BAC and EGG $P < 0.001$) and DM1M (BAC and EGG $P < 0.001$).

Mean Gastric Emptying Time (MGET) and Mean Cecum Arrival Time (MCAT)

Figure 2C represents the mean values of MGET and MCAT for all groups. Regarding MGET, the diabetes models showed an increase in gastric emptying time (min), (DM1W 109.85 ± 1.79 , $P = 0.003$), (DM1M 110.68 ± 1.34 , $P < 0.001$) and (DMmild 115.35 ± 1.45 , $P < 0.001$) compared to CT (102.45 ± 1.47). There was no significant difference in the MGET among the diabetes models. The MCAT was higher in diabetic rats, with (DM1W 288.45 ± 1.54 , $P < 0.001$), (DM1M 277 ± 1.64 , $P < 0.001$) and (DMmild 275.45 ± 1.19 , $P < 0.001$) compared to CT (261.05 ± 1.50). There was a significant increase of MCAT in DM1W compared to DM1M ($P < 0.001$) and DMmild ($P < 0.001$).

Histological analysis

Morphometry results shown in figure 2D. The circular muscle layer showed a significant thickening in the diabetic groups (DM1W $231,14 \pm 14,60$, $P < 0.001$), (DM1M $254,25 \pm 18,16$, $P < 0.001$) and (DMmild $268,64 \pm 16,57$, $P < 0.001$) compared to CT ($160,68 \pm 10,22$). Diabetic groups showed a significant thickening of mucosa (DM1W $638,35 \pm 28,09$, $P < 0.001$), (DM1M $675,09 \pm 30,54$, $P < 0.001$) and (DMmild $619,48 \pm 28,27$, $P = 0.009$) compared to the CT ($488,49 \pm 10,37$). There was no difference among the models of diabetes. The longitudinal layer showed no significant difference among the studied groups.

Immunohistochemistry

Figure 2E quantified the number of neurons per ganglion, and there is no difference among the markers and studied groups. In the figure 2F, the ChAT neurons of the diabetic animals (DM1M 432.93 ± 10.92 , $P < 0.001$) and (DMmild 369.20 ± 17.44 , $P < 0.001$) presented decreased of profile neuronal area compared to CT (635.44 ± 18.85). DM1W (600.34 ± 15.61) animals showed no significant difference compared to CT, but showed to have a larger area than DM1M and DMmild ($P < 0.001$). The nNOS neurons of the diabetic animals (DM1M 430.68 ± 13.67 , $P < 0.001$) and (DMmild 414.59 ± 18.03 , $P < 0.001$) presented decreased of profile neuronal area compared to CT (703.25 ± 25.72). DM1W (660.53 ± 24.04) animals showed no significant difference compared to CT, but exhibit to have a larger area than DM1M and DM mild ($P < 0.001$). The HuC/D neurons of the diabetic animals (DM1M 431.47 ± 11.99 , $P < 0.001$) and (DMmild 387.02 ± 14.15 , $P < 0.001$) presented decreased of profile neuronal area compared to CT (622.56 ± 15.40). DM1W (579.25 ± 16.21) animals showed no significant difference compared to CT, but present to have a larger area than DM1M and DM mild ($P < 0.001$).

Figure 4 shows the images of the double labeling of ChAT and HuC/D antibodies and the nuclei by DAPI in the myenteric plexus for all groups. Figure 5 shows the images of the double labeling of the nNOS, HuC/D, and DAPI antibodies.

DISCUSSION

In our results we found disturbances in the frequency of gastric contraction, slowing of gastric emptying and oro-cecal transit in different experimental models of diabetes. The data showed a decrease in the profile of the neuronal area of nitrergic and cholinergic neurons, suggesting that in diabetic rats morphometric changes of these neurons occur due to the time of exposure to different hyperglycemic conditions. These changes in neurons may indicate future degeneration and loss of function of the innervated tissue^[33,37], but it has already been possible to diagnose disorders of gastrointestinal motility, as well as structural changes, occurred in the gastric wall of diabetic groups, such as thickening of the mucosa and the circular muscular layer of the stomach. This event may be

associated with remodeling after tissue damage^[17], and have consequences on gastric contractility.

Damage caused by diabetes in the GIT may be related to glycemic levels and the time of exposure to hyperglycemia^[12]. The influence of glycemia was evidenced in the results of the one-week severe (DM1W) induced diabetes group, which presented decreased contraction frequency, slowing of emptying and gastrointestinal transit, and thickening of the gastric wall, but there were no morphometric changes in ChAT and nNOS neurons. Thus, disorders of gastrointestinal motility found in diabetes may occur before damage to enteric neurons, perhaps due to the influence of hyperglycemia on GIT^[33,37]. On the other hand, in the one-month-induced animals (DM1M) and the DMmild group, morphometric alterations were already present in the enteric neurons, as well as changes in the motility and morphometry of the gastric wall.

The results of DM1M and DMmild groups for GI motility, gastric wall morphometry, and enteric neurons were similar, even though mild diabetes had lower glycemic levels. The hypothesis is that DMmild animals were exposed to hyperglycemic conditions for a longer time because they were induced to diabetes on the first day of life. However, this model of moderate diabetes is very controversial, with different methodologies in the animal age literature and the induction form^[30,38,39].

AC Biosusceptometry (ACB) is a simple, inexpensive and sensitive technique, reproducible in several areas of research. This technique has already validated as capable of measuring gastric contraction activity^[40]. As well as for evaluation of gastric emptying and oro-cecal transit in rats ^[35,41]. For studies on gastrointestinal motility, it is essential to evaluate the mechanical and electrical activities of the smooth muscle. Electrogastrogram (EGG) is a rather simple, minimally invasive technique used mainly in researches on gastric electrical activity. Understanding the motor and electrical functions of GIT are essential in research on comorbidities related to gastrointestinal disorders^[42,43]. In our data, there was no difference between the electrical activity measured by EGG and the mechanical activity measured by the ACB in all the studied groups. However, it has reported a decrease

in the electrical signal coupling about the mechanical signal in long-term diabetic rats^[13].

Many studies have shown alterations in gastric motility in diabetes^[3,42,44], such as impairment of electrical activity, reduction of basal tonus and contraction^[45]. Our results indicate a decrease in the frequency of gastric contraction and increase of the half bandwidth in the DM1W, DM1M and DMmild diabetes models compared to CT. Our data suggest a decrease in contractility and the presence of gastric arrhythmias. The literature reports increased gastric arrhythmias and Abnormal rhythmic index (ARI) in models of severe and moderate diabetes with more than three months of induction^[12,13]. In these studies, no changes were reported in the frequency of gastric contraction, besides studying long-term experimental models of diabetes^[12,13].

There is concordance in most of the results regarding the slowing of gastric emptying (GE) in diabetes^[44,46–49]. This changes in GE corroborates with the results of our DM models used. There are also studies showing accelerated gastric emptying in diabetes^[12,50]. The use of obese diabetic mouse models showed that hyperglycemia causes an increase in *Cajal* cells in the stomach, triggered by the activation of proliferation pathways and cell survival, leading to increased gastric emptying^[52].

Disturbances in oro-cecal transit were also found in diabetes^[45]. In our results, the DM1W, DM1M, and DMmild groups showed an increase in MCAT time about to CT. Studies with long-term experimental models of diabetes report structural changes in the small intestine such as circular muscle thickening and longer organ length in diabetic rats. However, these structural alterations do not affect the time of intestinal transit by mechanisms of adaptation to the damages caused by diabetes^[45]. There is little knowledge about the changes in intestinal transit and if there is any relation with other disorders of the GIT ^[53] in diabetes.

Abnormalities in smooth muscle GI may also play a relevant role in the gastrointestinal disorders of diabetics^[54]. Morphofunctional changes of the gastrointestinal wall, such as thickening of the colon wall, and intestinal wall stiffness have been reported in diabetic rats^[17].

A 3D distribution of the volume and complacency of the stomach regions showed that there is a decrease in compliance in the stomach fund of diabetic rats^[55]. The hypothesis is that the thickening of the layers of the gastrointestinal wall occurs because the mucosa is injured continuously by the high concentration of glucose and the formation of oxidative stress. Mucosal damage can make the outer wall tenser and is stimulated to thicken by biomechanical processes. This process was called remodeling^[56,57]. Our data corroborate with the literature, finding an expressive thickening of the mucosa and circular muscular layer of the diabetic models. However, there is still little knowledge of the molecular mechanisms of these morphometric changes, and how they are related to disorders of gastrointestinal motility^[17,37,45].

The morphometry of enteric neurons was already evaluated in the duodenum, jejunum, ileum, and colon of STZ-induced rats at 1 to 9 weeks. There is a conflict between results of neuronal area morphometry, and show a possible increase^[33,58] or decreased cell body area^[37], but the mechanisms are unknown^[37,58].

It is known that diabetes can trigger cell death and degeneration of enteric neurons^[25,28,59,60]. It has been demonstrated that hyperglycemia can lead to the loss of inhibitory (nNOS) and excitatory enteric neurons (ChAT)^[59,60]. However, there is little knowledge of the temporal relationship of neuronal damage to glycemic levels in experimental models of diabetes.

Most of the mechanisms proposed to explain tissue and neuronal damage of GIT in diabetes are related to oxidative stress^[61,62]. Hyperglycemia in DM can increase levels of oxidative stress, which is related to the production of advanced glycation endproducts (AGEs) and reactive oxygen species (ROS)^[47,63]. The formation of AGEs in cells and tissues leads to changes in intracellular signaling related to cell death^[64]. The accumulation of these molecules and their deleterious effects are related to the duration of diabetes and the degree of glycemic control^[25,65]. Some studies suggest that nNOS neurons are more susceptible to damage caused by hyperglycemia. The NOS enzyme is Ca^{2+} dependent, and the increase in cytoplasmic Ca^{2+} may produce excessive levels of nitric oxide (NO). In the presence of ROS, NO can react with O_2^- to produce peroxynitrite (ONOO^-), which

nitrosylates tyrosine residues in proteins, damaging protein function and possibly compromising DNA^[63].

Studies on ChAT neurons in diabetes are contradictory. Some studies indicate an increase in the density of ChAT neurons in the myenteric plexus in the ileum and duodenum and may be related to the increase in contractility and arrhythmias^[28]. Another work indicates a decrease in both ChAT and nNOS neurons in the colon of rats induced STZ at 12 weeks^[26].

Our results indicate a decrease in the neuronal area of nitrergic and cholinergic neurons in the stomach, suggesting that in the DM1M and DMmild models, there is a decrease in the cell body area of these neurons. In conclusion, changes in motility appear to be associated with changes in the gastric wall and a decrease in the neuronal area of nitrergic and cholinergic neurons, which were intensified by prolonged exposure to hyperglycemic conditions, even if moderate in diabetes.

Future work should be applied in the discovery of possible molecular mechanisms responsible for the decrease of the profile of the enteric neuron area, and how this process is related to the pathophysiology of the disorders in the gastrointestinal motility found in diabetes.

REFERENCES

1. **Ma RCW.** Epidemiology of diabetes and diabetic complications in China. *Diabetologia* 2018;**61**:1249–60 [PMID: 29700561 PMID:29700561DOI: 10.1007/s00125-018-4557-7]
2. **Chan M.** Global report on diabetes. *World Heal Organ* 2014;**58**:1–88 [PMID: 25246403 PMID:25246403DOI: 10.1128/AAC.03728-14]
3. **De Block CEM, De Leeuw IH, Pelckmans PA, Van Gaal LF.** Current concepts in gastric motility in diabetes mellitus. *Curr Diabetes Rev* 2006;**2**:113–30 [PMID:DOI: 10.2174/157339906775473662]
4. **Nilsson PH.** Diabetic gastroparesis: A review. *J Diabetes Complications* 1996;**10**:113–22 [PMID: 8777330 PMID:8777330DOI: 10.1016/1056-8727(96)00001-3]
5. **Spångéus A, El-Salhy M, Suhr O, Eriksson J, Lithner F, et al.** Prevalence of Gastrointestinal Symptoms in Young and Middle-Aged Diabetic Patients Prevalence of Gastrointestinal Symptoms in Young and Middle-Aged Diabetic Patients. *Scand J Gastroenterol* 1999;**34**:1196–202 [PMID:DOI: 10.1080/003655299750024706]
6. **Jebbink HJ, Bruijs PP, Bravenboer B, Akkermans LM, vanBerge-Henegouwen GP, et al.** Gastric myoelectrical activity in patients with type I diabetes mellitus and autonomic neuropathy. *Dig Dis Sci* 1994;**39**:2376–83 [PMID: 7956606 PMID:7956606DOI:]
7. **Mard SA, Ahmadi I, Ahangarpour A, Gharib-Naseri MK, Badavi M.** Delayed gastric emptying in diabetic rats caused by decreased expression of cystathionine gamma lyase and H₂S synthesis: in vitro and in vivo studies. *Neurogastroenterol Motil* 2016;**28**:1677–89 [PMID:DOI: 10.1111/nmo.12867]
8. **Samsom M, Akkermans LMA, Jebbink RJA, Isselt H Van, van Isselt H, et al.** Gastrointestinal motor mechanisms in hyperglycaemia induced delayed gastric emptying in type I diabetes mellitus. *Gut* 1997;**40**:641–6 [PMID: 9203944 PMID:9203944DOI:]
9. **Woerle HJ, Albrecht M, Linke R, Zschau S, Neumann C, et al.** Impaired hyperglycemia-induced delay in gastric emptying in patients with type 1 diabetes deficient for islet amyloid polypeptide. *Diabetes Care* 2008;**31**:2325–31 [PMID: 19033417 PMID:19033417DOI: 10.2337/dc07-2446]
10. **Choi KM, Zhu J, Stoltz GJ, Vernino S, Camilleri M, et al.** Determination of gastric emptying in nonobese diabetic mice. *Am J Physiol Gastrointest Liver Physiol* 2007;**293**:G1039–45 [PMID: 17884976 PMID:17884976DOI: 10.1152/ajpgi.00317.2007]

11. **Bharucha AE, Kudva Y, Basu A, Camilleri M, Low PA, et al.** Relationship between glycemic control and gastric emptying in poorly controlled type 2 diabetes. *Clin Gastroenterol Hepatol* 2015;**13**:466–76 [PMID: 25041866 PMID:25041866DOI: 10.1016/j.cgh.2014.06.034]
12. **Hauschildt AT, Corá LA, Volpato GT, Sinzato YK, Damasceno DC, et al.** Mild diabetes: Long-term effects on gastric motility evaluated in rats. *Int J Exp Pathol* 2018;[PMID: 29479759 PMID:29479759DOI: 10.1111/iepm.12262]
13. **Marques RG, Americo MF, Spadella CT, Corá L a, Oliveira RB, et al.** Different patterns between mechanical and electrical activities: an approach to investigate gastric motility in a model of long-term diabetic rats. *Physiol Meas* 2014;**35**:69–81 [PMID: 24345922 PMID:24345922DOI: 10.1088/0967-3334/35/1/69]
14. **Marathe CS, Rayner CK, Jones KL, Horowitz M.** Relationships between gastric emptying, postprandial glycemia, and incretin hormones. *Diabetes Care* 2013;**36**:1396–405 [PMID: 23613599 PMID:23613599DOI: 10.2337/dc12-1609]
15. **Ebert EC.** Gastrointestinal complications of diabetes mellitus. *Disease-a-Month* 2005;**51**:620–63 [PMID: 16458726 PMID:16458726DOI: 10.1016/j.disamonth.2005.11.002]
16. **Furness JB.** The enteric nervous system and neurogastroenterology. *Nat Rev Gastroenterol Hepatol* 2012;**9**:286–94 [PMID: 22392290 PMID:22392290DOI: 10.1038/nrgastro.2012.32]
17. **Zhao J, Nakaguchi T, Gregersen H.** Biomechanical and histomorphometric colon remodelling in STZ-Induced diabetic rats. *Dig Dis Sci* 2009;**54**:1636–42 [PMID: 18989775 PMID:18989775DOI: 10.1007/s10620-008-0540-3]
18. **Furness JB.** Types of neurons in the enteric nervous system. *J Auton Nerv Syst* 2000;**81**:87–96 [PMID: 10869706 PMID:10869706DOI: 10.1016/S0165-1838(00)00127-2]
19. **Camilleri M.** Diabetic Gastroparesis. 2007;**8** [PMID:DOI: 10.1056/NEJMcp062614]
20. **Camilleri M, Bharucha AE, Farrugia G.** Epidemiology, Mechanisms, and Management of Diabetic Gastroparesis. *Clin Gastroenterol Hepatol* 2011;**9**:5–12 [PMID: 20951838 PMID:20951838DOI: 10.1016/j.cgh.2010.09.022]
21. **Chandrasekharan B, Srinivasan S.** Diabetes and the enteric nervous system. *Neurogastroenterol Motil* 2007;**19**:951–60 [PMID: 17971027 PMID:17971027DOI: 10.1111/j.1365-2982.2007.01023.x]

22. **Neshatian L, Gibbons SJ, Farrugia G.** Macrophages in diabetic gastroparesis - The missing link? *Neurogastroenterol Motil* 2015;**27**:7–18 [PMID: 25168158 PMID:25168158DOI: 10.1111/nmo.12418]
23. **Wang XY, Huizinga JD, Diamond J, Liu LWC.** Loss of intramuscular and submuscular interstitial cells of Cajal and associated enteric nerves is related to decreased gastric emptying in streptozotocin-induced diabetes. *Neurogastroenterol Motil* 2009;**21**:1095–107 [PMID: 19566589 PMID:19566589DOI: 10.1111/j.1365-2982.2009.01336.x]
24. **Wood JD.** Enteric Nervous System: Neuropathic Gastrointestinal Motility. *Dig Dis Sci* 2016;**61**:1803–16 [PMID: 27142673 PMID:27142673DOI: 10.1007/s10620-016-4183-5]
25. **Cellek S, Qu W, Schmidt AM, Moncada S.** Synergistic action of advanced glycation and products and endogenous nitric oxide leads to neuronal apoptosis in vitro: A new insight into selective nitroergic neuropathy in diabetes. *Diabetologia* 2004;**47**:331–9 [PMID: 14676945 PMID:14676945DOI: 10.1007/s00125-003-1298-y]
26. **Du F, Wang L, Qian W, Liu S.** Loss of enteric neurons accompanied by decreased expression of GDNF and PI3K/ Akt pathway in diabetic rats. *Neurogastroenterol Motil* 2009;**21**:1229–35 [PMID: 19709371 PMID:19709371DOI: 10.1111/j.1365-2982.2009.01379.x]
27. **Watkins CC, Sawa A, Jaffrey S, Blackshaw S, Barrow RK, et al.** Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy. *J Clin Invest* 2000;**106**:373–84 [PMID: 10930440 PMID:10930440DOI: 10.1172/JCI8273]
28. **Cellek S, Foxwell NA, Moncada S.** Two phases of nitroergic neuropathy in streptozotocin-induced diabetic rats. *Diabetes* 2003;**52**:2353–62 [PMID: 12941776 PMID:12941776DOI: 10.2337/diabetes.52.9.2353]
29. **Damasceno DC, Netto AO, Iessi IL, Gallego FQ, Corvino SB, et al.** Streptozotocin-induced diabetes models: Pathophysiological mechanisms and fetal outcomes. *Biomed Res Int* 2014;**2014** [PMID: 24977161 PMID:24977161DOI: 10.1155/2014/819065]
30. **Damasceno DC, Sinzato YK, Bueno A, Netto AO, Dallaqua B, et al.** Mild diabetes models and their maternal-fetal repercussions. *J Diabetes Res* 2013;**2013** [PMID: 23878822 PMID:23878822DOI: 10.1155/2013/473575]
31. **I.L. I, A. B, Y.K. S, K.N. T, M.V. R, et al.** Evaluation of neonatally-induced mild diabetes in rats: Maternal and fetal repercussions. *Diabetol Metab Syndr* 2010;**2**:1–8 [PMID:DOI: 10.1186/1758-5996-2-37]

32. **Merzouk H, Madani S, Chabane Sari D, Prost J, Bouchenak M, et al.** Time course of changes in serum glucose, insulin, lipids and tissue lipase activities in macrosomic offspring of rats with streptozotocin-induced diabetes. *Clin Sci* 2000;**98**:21–30 [PMID: 10600655 PMID:10600655DOI: 10.1042/CS19990109]
33. **Fregonesi CEPT, De Miranda-Neto MH, Molinari SL, Zanoni JN.** Quantitative study of the myenteric plexus of the stomach of rats with streptozotocin-induced diabetes. *Arq Neuropsiquiatr* 2001;**59**:50–3 [PMID: 11299431 PMID:11299431DOI: 10.1590/S0004-282X2001000100011]
34. **Sato KL, Migliaccio V, Do Carmo JM, Oliveti MCDDBB, Ferreira RS, et al.** Diabetes como modelo de neuropatia auton??mica. *Medicina (B Aires)* 2006;**39**:28–38
35. **Quini CC, Américo MF, Corá L a, Calabresi MF, Alvarez M, et al.** Employment of a noninvasive magnetic method for evaluation of gastrointestinal transit in rats. *J Biol Eng* 2012;**6**:6 [PMID: 22587220 PMID:22587220DOI: 10.1186/1754-1611-6-6]
36. **Podczek F, Newton JM, Yuen KH.** The Description of the Gastrointestinal Transit of Pellets Assessed by Gamma Scintigraphy Using Statistical Moments. *Pharm. Res. An Off. J. Am. Assoc. Pharm. Sci.*1995;**12**:376–9 [PMID: 7617524 PMID:7617524DOI: 10.1023/A:1016200501563]
37. **Furlan MMDP, Molinari SL, De Miranda Neto MH.** Morphoquantitative effects of acute diabetes on the myenteric neurons of the proximal colon of adult rats. *Arq Neuropsiquiatr* 2002;**60**:576–81 [PMID: 12244395 PMID:12244395DOI:]
38. **Sachin A, Shreesh KO, Divya V.** Characterization of Streptozotocin Induced Diabetes Mellitus in Swiss Albino Mice. *Glob J Pharmacol* 2009;**3**:81–4 [PMID:DOI: 10.13040/ijpsr.0975-8232]
39. **Sinzato YK, Volpato GT, Iessi IL, Bueno A, Calderon IDMP, et al.** Neonatally induced mild diabetes in rats and its effect on maternal, placental, and fetal parameters. *Exp Diabetes Res* 2012;**2012** [PMID: 22778712 PMID:22778712DOI: 10.1155/2012/108163]
40. **Américo MF, Oliveira RB, Corá L a, Marques RG, Romeiro FG, et al.** The ACB technique: a biomagnetic tool for monitoring gastrointestinal contraction directly from smooth muscle in dogs. *Physiol Meas* 2010;**31**:159–69 [PMID: 20009185 PMID:20009185DOI: 10.1088/0967-3334/31/2/003]
41. **Calabresi MFF, Quini CC, Matos JF, Moretto GM, Americo MF, et al.** Alternate current biosusceptometry for the assessment of gastric motility after proximal gastrectomy in rats: A feasibility study. *Neurogastroenterol Motil* 2015;[PMID:DOI: 10.1111/nmo.12660]

42. **Chen JD, Lin Z, Pan J, McCallum RW.** Abnormal gastric myoelectrical activity and delayed gastric emptying in patients with symptoms suggestive of gastroparesis. *Dig Dis Sci* 1996;**41**:1538–45 [PMID: 8769276 PMID:8769276DOI: 10.1007/BF02087897]
43. **Américo MF, Miranda JRA, Corá LA, Romeiro FG.** Electrical and mechanical effects of hyoscine butylbromide on the human stomach: A non-invasive approach. *Physiol Meas* 2009;**30**:363–70 [PMID: 19282558 PMID:19282558DOI: 10.1088/0967-3334/30/4/002]
44. **Cucchiara S, Franzese A, Salvia G, Alfonsi L, Iula VD, et al.** Gastric emptying delay and Gastric electrical derangement in IDDM. *Diabetes Care* 1998;**21**:438–43 [PMID: 9540029 PMID:9540029DOI: 10.2337/diacare.21.3.438]
45. **Domènech A, Pasquinelli G, de Giorgio R, Gori A, Bosch F, et al.** Morphofunctional changes underlying intestinal dysmotility in diabetic RIP-I/hIFN?? transgenic mice. *Int J Exp Pathol* 2011;**92**:400–12 [PMID: 22050417 PMID:22050417DOI: 10.1111/j.1365-2613.2011.00789.x]
46. **De Block CEM, De Leeuw IH, Pelckmans PA, Callens D, Máday E, et al.** Delayed gastric emptying and gastric autoimmunity in type 1 diabetes. *Diabetes Care* 2002;**25** [PMID:DOI: 10.2337/diacare.25.5.912]
47. **Chandrasekharan B, Anitha M, Blatt R, Shahnavaz N, Kooby D, et al.** Colonic motor dysfunction in human diabetes is associated with enteric neuronal loss and increased oxidative stress. *Neurogastroenterol Motil* 2011;**23**:131–9 [PMID: 20939847 PMID:20939847DOI: 10.1111/j.1365-2982.2010.01611.x]
48. **Wilson KPMLA, Parkman MVNHP, Nguyen RWMLA.** Relating gastric scintigraphy and symptoms to motility capsule transit and pressure findings in suspected gastroparesis. 2018;1–12 [PMID:DOI: 10.1111/nmo.13196]
49. **Hu W, Feng P.** Myosin Light Chain Kinase Is Involved in the Mechanism of Gastrointestinal Dysfunction in Diabetic Rats. 2012;1197–202 [PMID:DOI: 10.1007/s10620-012-2041-7]
50. **Phillips WT, Schwartz JG, McMahan C a.** Rapid gastric emptying of an oral glucose solution in type 2 diabetic patients. *J Nucl Med* 1992;**33**:1496–500 [PMID: 1634941 PMID:1634941DOI:]
51. **Hayashi Y, Toyomasu Y, Saravanaperumal SA, Bardsley MR, Smestad JA, et al.** Hyperglycemia Increases Interstitial Cells of Cajal via MAPK1 and MAPK3 Signaling to ETV1 and KIT, Leading to Rapid Gastric Emptying. *Gastroenterology* 2017;**153**:521–535.e20 [PMID:DOI: 10.1053/j.gastro.2017.04.020]

52. **Miranda RA, Cora LA.** PHARMACEUTICAL TECHNOLOGY AC Biosusceptometry Technique to Evaluate the Gastrointestinal Transit of Pellets under Influence of Prandial State. 2010;**99**:317–24 [PMID:DOI: 10.1002/jps]
53. **T.V. Nowak, B.Harrington, J.P.Weisbruch and JHK.** Structural and functional characteristics of muscle from diabetic rodent small intestine. *Gastrointest Liver Physiol* 1990;
54. **Liao D, Zhao J, Gregersen H.** Three-dimensional geometry analysis of the stomach in type II diabetic GK rats. *Diabetes Res Clin Pract* 2006;**71**:1–13 [PMID: 16054265 PMID:16054265DOI: 10.1016/j.diabres.2005.05.016]
55. **Zhao J, Yang J, Gregersen H.** Biomechanical and morphometric intestinal remodelling during experimental diabetes in rats. *Diabetologia* 2003;**46**:1688–97 [PMID: 14593459 PMID:14593459DOI: 10.1007/s00125-003-1233-2]
56. **Zhao J, Liao D, Gregersen H.** Biomechanical and histomorphometric esophageal remodeling in type 2 diabetic GK rats. *J Diabetes Complications* 2007;**21**:34–40 [PMID: 17189872 PMID:17189872DOI: 10.1016/j.jdiacomp.2005.12.001]
57. **De Miranda MH, Defani MA, Fregonesi CEPT, Natali MRM, Pereira A.** Morphometric and quantitative evaluation of the NADH-diaphorase positive myenteric neurons of the jejunum of streptozotocin-diabetic rats supplemented with acetyl-L-carnitine. *J Vet Med Ser C Anat Histol Embryol* 2005;**34**:154–8 [PMID:DOI: 10.1111/j.1439-0264.2005.00585.x]
58. **Anitha M, Gondha C, Sutliff R, Parsadanian A, Mwangi S, et al.** GDNF rescues hyperglycemia-induced diabetic enteric neuropathy through activation of the PI3K/Akt pathway. *J Clin Invest* 2006;**116**:344–56 [PMID: 16453021 PMID:16453021DOI: 10.1172/JCI26295]
59. **Takahashi T.** Pathophysiological significance of neuronal nitric oxide synthase in the gastrointestinal tract. *J Gastroenterol* 2003;**38**:421–30 [PMID: 12768383 PMID:12768383DOI: 10.1007/s00535-003-1094-y]
60. **Yu T, Zheng Y, Wang Y, Xiong W, Lin L.** Advanced glycation end products interfere with gastric smooth muscle contractile marker expression via the AGE / RAGE / NF- κ B pathway. *Exp Mol Pathol* 2017;**102**:7–14 [PMID:DOI: 10.1016/j.yexmp.2016.12.002]
61. **Andrade V De, Silva-santos E, Olair DM, Beltrame C, Fernanda M, et al.** Vitamin C Improves Gastroparesis in Diabetic Rats : Effects on Gastric Contractile Responses and Oxidative Stress. 2017;2338–47 [PMID:DOI: 10.1007/s10620-017-4632-9]
62. **Rivera LR, Poole DP, Thacker M, Furness JB.** The involvement of nitric oxide synthase neurons in enteric neuropathies. *Neurogastroenterol Motil* 2011;**23**:980–8 [PMID: 21895878 PMID:21895878DOI: 10.1111/j.1365-2982.2011.01780.x]

63. **King RHM.** The role of glycation in the pathogenesis of diabetic polyneuropathy. *Mol Pathol* 2001;**54**:400–8 [PMID: 11724915 PMID:11724915DOI:]
64. **Vincent AM, Perrone L, Sullivan KA, Backus C, Sastry AM, et al.** Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. *Endocrinology* 2007;**148**:548–58 [PMID: 17095586 PMID:17095586DOI: 10.1210/en.2006-0073]




Figure 1 Profile of gastric motility signals measured by ACB. The left column shows the profile of the signal acquired and the right column shows the dominant frequencies quantified by the FFT for all animals analyzed. The arrows indicate the dominant frequency of each profile around the dotted line indicate average frequency of 4 CPM.




Figure 2 Analysis of gastrointestinal motility and morphometry of the gastric wall and enteric neurons of diabetic and control rats. A: glycemic values and body weight of the all animals studied (^a $P \leq 0,001$ for DM1W and DM1M; $P \leq 0,05$ for DMmild, all groups compared to CT). B: Frequency gastric and half-bandwidth mensured for BAC e EGG in the groups (^a $P \leq 0,001$ and ^b $P = 0,007$ for DM1W; ^a $P \leq 0,001$ and ^c $P = 0,001$ for DM1M; ^a $P \leq 0,001$ and ^d $P = 0,006$ for DM mild; all compared to CT), only in the half-bandwidth difference between the models of diabetes occurred, DMmild compared to DM1W (BAC and EGG ^a $P < 0.001$) and DM1M (BAC and EGG ^a $P < 0.001$). C: MGET and MCAT results (^e $P = 0,003$ and ^a $P \leq 0,001$ for DM1W; ^a $P \leq 0,001$ for DM1M and DMmild; all compared to CT), only in the MACT difference between the models of diabetes occurred, DM1W compared to DM1M ($P < 0.001$) and DMmild ($P < 0.001$). D: perimeter of the muscular layers and mucosa of the stomach (^a $P \leq 0,001$ for DM1W and DM1M;

^fP=0,009 for DM mild; all compared to CT). E: quantification of the number of neurons (ChAT, nNOS and HuC/D) per ganglia labeled with the respective antibodies. F: neuronal profile area (μm^2) of the cell bodies (ChAT, nNOS and HuC/D) labeled with the respective antibodies (^aP $\leq$ 0,001 for DM1M and DMmild compared to CT), DM1M and DMmild showed smaller area than DM1W (P<0,001).




Figure 3 Analysis of the muscular layers of the stomach of all groups using HE staining. M = musosa, CM = circular muscle, LM = longitudinal muscle. Scale bar= Scale bars: 50 μm .




Figure 4 Colocalization of HuC/D immunoreactivity with ChAT immunoreactivity in neurons of the stomach myenteric plexus in the diabetic and control animals. ChAT (A, B, C e D), HuC/D ('A,'B,'C e 'D), DAPI (''A,''B,''C e ''D) and Merge ('''A,''B,''C e '''D). The arrows indicate ChAT that colocalized with HuC/D ('''A,''B,''C e '''D). Scale bars: 50 μ m.




Figure 5 Colocalization of HuC/D immunoreactivity with NOS immunoreactivity in neurons of the stomach myenteric plexus in the diabetic and control animals. NOS (A, B, C e D), HuC/D ('A,'B,'C e 'D), DAPI (''A,'B,'C e ''D) and Merge ('''A,'''B,'''C e '''D). The arrows indicate NOS that colocalized with HuC/D ('''A,'''B,'''C e '''D). Scale bars: 50 μ m

Conclusões

3. Conclusões

Nossos resultados apresentaram diminuição da contratilidade gástrica, aumento do índice de arritmias, lentificação do esvaziamento e trânsito oro-cecal. Assim como foi encontrado espessamento das camadas da parede gástrica, diminuição da área (μm^2) do corpo celular de neurônios nitrérgicos e colinérgicos. Sugerindo que em modelos de diabetes grave e moderado ocorrem mudanças morfométricas relacionadas ao tempo de exposição a condições hiperglicêmicas. Essas mudanças neuronais e histológicas podem indicar uma futura degeneração, morte celular e perda de função do tecido innervado, porém já foi possível diagnosticar distúrbios da motilidade gastrointestinal. Em conclusão, alterações na motilidade parecem estar associadas a mudanças na parede gástrica e à diminuição da área neuronal de neurônios nitrérgicos e colinérgicos, que foram intensificados pela exposição prolongada a condições hiperglicêmicas, mesmo que moderadas no diabetes.

Referências

4. Referências

- AMÉRICO, M. F.; OLIVEIRA, R. B.; CORÁ, L. a; MARQUES, R. G.; ROMEIRO, F. G.; ANDREIS, U.; MIRANDA, J. R. a. The ACB technique: a biomagnetic tool for monitoring gastrointestinal contraction directly from smooth muscle in dogs. **Physiological measurement**, [s. l.], v. 31, n. 2, p. 159–69, 2010. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/20009185>>
- BHARUCHA, A. E.; KUDVA, Y.; BASU, A.; CAMILLERI, M.; LOW, P. A.; VELLA, A.; ZINSMEISTER, A. R. Relationship between glycemic control and gastric emptying in poorly controlled type 2 diabetes. **Clinical Gastroenterology and Hepatology**, [s. l.], v. 13, n. 3, p. 466–476, 2015. Disponível em: <<http://dx.doi.org/10.1016/j.cgh.2014.06.034>>
- BOECKXSTAENS, G.; CAMILLERI, M.; SIFRIM, D.; HOUGHTON, L. A.; ELSENBURCH, S.; LINDBERG, G.; AZPIROZ, F.; PARKMAN, H. P. Fundamentals of neurogastroenterology: Physiology/motility - Sensation. **Gastroenterology**, [s. l.], v. 150, n. 6, p. 1292–1304e2, 2016. Disponível em: <<http://dx.doi.org/10.1053/j.gastro.2016.02.030>>
- CAMILLERI, M. Diabetic Gastroparesis. [s. l.], v. 8, 2007.
- CAMILLERI, M.; BHARUCHA, A. E.; FARRUGIA, G. Epidemiology, Mechanisms, and Management of Diabetic Gastroparesis. **Clinical Gastroenterology and Hepatology**, [s. l.], v. 9, n. 1, p. 5–12, 2011. Disponível em: <<http://dx.doi.org/10.1016/j.cgh.2010.09.022>>
- CAMILLERI, M.; BROWN, M. L.; MALAGELADA, J. R. Relationship between impaired gastric emptying and abnormal gastrointestinal motility. **Gastroenterology**, [s. l.], v. 91, n. 1, p. 94–99, 1986.
- CELLEK, S.; FOXWELL, N. A.; MONCADA, S. Two phases of nitroergic neuropathy in streptozotocin-induced diabetic rats. **Diabetes**, [s. l.], v. 52, n. 9, p. 2353–2362, 2003.
- CELLEK, S.; QU, W.; SCHMIDT, A. M.; MONCADA, S. Synergistic action of advanced glycation and products and endogenous nitric oxide leads to neuronal apoptosis in vitro: A new insight into selective nitroergic neuropathy in diabetes. **Diabetologia**, [s. l.], v. 47, n. 2, p. 331–339, 2004.
- CHAN, M. Global report on diabetes. **World Health Organization**, [s. l.], v. 58, n. 12, p. 1–88, 2014. Disponível em: <http://www.who.int/about/licensing/copyright_form/index.html>. %0AThe>
- CHANDRASEKHARAN, B.; SRINIVASAN, S. Diabetes and the enteric nervous system. **Neurogastroenterology and motility: the official journal of the European Gastrointestinal Motility Society**, [s. l.], v. 19, n. 12, p. 951–60, 2007. Disponível em: <<http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3711013&tool=pmcentrez&rendertype=abstract>>

CHEN, J. D.; LIN, Z.; PAN, J.; MCCALLUM, R. W. Abnormal gastric myoelectrical activity and delayed gastric emptying in patients with symptoms suggestive of gastroparesis. **Digestive diseases and sciences**, [s. l.], v. 41, n. 8, p. 1538–1545, 1996. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/8769276>>

CHOI, K. M.; ZHU, J.; STOLTZ, G. J.; VERNINO, S.; CAMILLERI, M.; SZURSZEWSKI, J. H.; GIBBONS, S. J.; FARRUGIA, G. Determination of gastric emptying in nonobese diabetic mice. **American journal of physiology. Gastrointestinal and liver physiology**, [s. l.], v. 293, n. 5, p. G1039-45, 2007. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/17884976>>

CUMMINGS, D. E.; OVERDUIN, J. Review series Gastrointestinal regulation of food intake. **The Journal of Clinical Investigation**, [s. l.], v. 117, n. 1, p. 13–23, 2007. Disponível em: <<http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1716217&tool=pmcentrez&rendertype=abstract>>

DAMASCENO, D. C.; NETTO, A. O.; IESSI, I. L.; GALLEGGO, F. Q.; CORVINO, S. B.; DALLAQUA, B.; SINZATO, Y. K.; BUENO, A.; CALDERON, I. M. P.; RUDGE, M. V. C. Streptozotocin-induced diabetes models: Pathophysiological mechanisms and fetal outcomes. **BioMed Research International**, [s. l.], v. 2014, 2014.

DAMASCENO, D. C.; SINZATO, Y. K.; BUENO, A.; NETTO, A. O.; DALLAQUA, B.; GALLEGGO, F. Q.; IESSI, I. L.; CORVINO, S. B.; SERRANO, R. G.; MARINI, G.; PICULO, F.; CALDERON, I. M. P.; RUDGE, M. V. C. Mild diabetes models and their maternal-fetal repercussions. **Journal of Diabetes Research**, [s. l.], v. 2013, 2013.

DE BLOCK, C. E. M.; DE LEEUW, I. H.; BOGERS, J. J. P. M.; PELCKMANS, P. a.; IEVEN, M. M.; VAN MARCK, E. a. E.; VAN ACKER, K. L.; VAN GAAL, L. F. Autoimmune Gastropathy in Type 1 Diabetic Patients With Parietal Cell Antibodies. **Diabetes Care**, [s. l.], v. 26, n. 1, p. 82–88, 2003. Disponível em: <<http://care.diabetesjournals.org/content/26/1/82.abstract%5Cnhttp://care.diabetesjournals.org/content/26/1/82.full.pdf>>

DE BLOCK, C. E. M.; DE LEEUW, I. H.; PELCKMANS, P. A.; VAN GAAL, L. F. Current concepts in gastric motility in diabetes mellitus. **Current Diabetes Reviews**, [s. l.], v. 2, n. 1, p. 113–130, 2006.

DORSEY, J. L.; BECKER, M. H.; AL., E. Standards of Medical Care in Diabetes—2018. **Diabetes Care**, [s. l.], v. 41, n. Supplement 1, p. S55–S64, 2018. Disponível em: <<http://care.diabetesjournals.org/lookup/doi/10.2337/dc18-S006>>

DU, F.; WANG, L.; QIAN, W.; LIU, S. Loss of enteric neurons accompanied by decreased expression of GDNF and PI3K/Akt pathway in diabetic rats. **Neurogastroenterology and Motility**, [s. l.], v. 21, n. 11, p. 1229–1235, 2009.

EBERT, E. C. Gastrointestinal complications of diabetes mellitus. **Disease-a-Month**, [s. l.], v. 51, n. 12, p. 620–663, 2005.

FREGONESI, C. E. P. T.; DE MIRANDA-NETO, M. H.; MOLINARI, S. L.; ZANONI, J. N. Quantitative study of the myenteric plexus of the stomach of rats with streptozotocin-induced diabetes. **Arquivos de Neuro-Psiquiatria**, [s. l.], v. 59, n. 1, p. 50–53, 2001.

FURNESS, J. B. Types of neurons in the enteric nervous system. **Journal of the Autonomic Nervous System**, [s. l.], v. 81, n. 1–3, p. 87–96, 2000.

FURNESS, J. B. The enteric nervous system and neurogastroenterology. **Nature Reviews Gastroenterology and Hepatology**, [s. l.], v. 9, n. 5, p. 286–294, 2012. Disponível em: <<http://dx.doi.org/10.1038/nrgastro.2012.32>>

HAUSCHILDT, A. T.; CORÁ, L. A.; VOLPATO, G. T.; SINZATO, Y. K.; DAMASCENO, D. C.; AMÉRICO, M. F. Mild diabetes: Long-term effects on gastric motility evaluated in rats. **International Journal of Experimental Pathology**, [s. l.], 2018.

I.L., I.; A., B.; Y.K., S.; K.N., T.; M.V., R.; D.C., D. Evaluation of neonatally-induced mild diabetes in rats: Maternal and fetal repercussions.

Diabetology and Metabolic Syndrome, [s. l.], v. 2, n. 1, p. 1–8, 2010.

Disponível em:

<<http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L359207542%0Ahttp://dx.doi.org/10.1186/1758-5996-2-37>>

JANSSEN, P.; VANDEN BERGHE, P.; VERSCHUEREN, S.; LEHMANN, A.; DEPOORTERE, I.; TACK, J. Review article: The role of gastric motility in the control of food intake. **Alimentary Pharmacology and Therapeutics**, [s. l.], v. 33, n. 8, p. 880–894, 2011.

JEBBINK, H. J.; BRUIJS, P. P.; BRAVENBOER, B.; AKKERMANS, L. M.; VANBERGE-HENEGOUWEN, G. P.; SMOUT, A. J. Gastric myoelectrical activity in patients with type I diabetes mellitus and autonomic neuropathy. **Digestive diseases and sciences**, [s. l.], v. 39, n. 11, p. 2376–2383, 1994.

JOHNSON, L. **Gastrointestinal Physiology**. 8th. ed. [s.l: s.n.].

KELLEY, D.; MITRAKOU, A.; MARSH, H.; SCHWENK, F.; BENN, J.; SONNENBERG, G.; ARCANGELI, M.; AOKI, T.; SORENSEN, J.; BERGER, M.; SONKSEN, P.; GERICH, J. Skeletal muscle glycolysis, oxidation, and storage of an oral glucose load. **Journal of Clinical Investigation**, [s. l.], v. 81, n. 5, p. 1563–1571, 1988.

MA, R. C. W. Epidemiology of diabetes and diabetic complications in China. **Diabetologia**, [s. l.], v. 61, n. 6, p. 1249–1260, 2018.

MARATHE, C. S.; RAYNER, C. K.; JONES, K. L.; HOROWITZ, M. Relationships between gastric emptying, postprandial glycemia, and incretin hormones. **Diabetes Care**, [s. l.], v. 36, n. 5, p. 1396–1405, 2013.

MARD, S. A.; AHMADI, I.; AHANGARPOUR, A.; GHARIB-NASERI, M. K.;

BADAVI, M. Delayed gastric emptying in diabetic rats caused by decreased expression of cystathionine gamma lyase and H₂S synthesis: in vitro and in vivo studies. **Neurogastroenterology and Motility**, [s. l.], v. 28, n. 11, p. 1677–1689, 2016.

MARQUES, R. G.; AMERICO, M. F.; SPADELLA, C. T.; CORÁ, L. a; OLIVEIRA, R. B.; MIRANDA, J. R. a. Different patterns between mechanical and electrical activities: an approach to investigate gastric motility in a model of long-term diabetic rats. **Physiological measurement**, [s. l.], v. 35, n. 1, p. 69–81, 2014. Disponível em: <http://iopscience.iop.org/0967-3334/35/1/69/pdf/0967-3334_35_1_69.pdf>

NESHATIAN, L.; GIBBONS, S. J.; FARRUGIA, G. Macrophages in diabetic gastroparesis - The missing link? **Neurogastroenterology and Motility**, [s. l.], v. 27, n. 1, p. 7–18, 2015.

NILSSON, P. H. Diabetic gastroparesis: A review. **Journal of Diabetes and its Complications**, [s. l.], v. 10, n. 2, p. 113–122, 1996.

QUINI, C. C.; AMÉRICO, M. F.; CORÁ, L. A.; CALABRESI, M. F. F.; ALVAREZ, M.; OLIVEIRA, R. B.; MIRANDA, J. R. A. Employment of a noninvasive magnetic method for evaluation of gastrointestinal transit in rats. **Journal of Biological Engineering**, [s. l.], v. 6, p. 1–7, 2012.

RIDDLE, M. C. et al. **Standard medical care in diabetes 2018**. [s.l: s.n.]. v. 41 Disponível em: <<http://diabetesed.net/wp-content/uploads/2017/12/2018-ADA-Standards-of-Care.pdf>>

SAMSOM, M.; AKKERMANS, L. M. A.; JEBBINK, R. J. A.; ISSELT, H. Van; VAN ISSELT, H.; VANBERGE-HENEGOUWEN, G. P.; SMOUT, A. J. Gastrointestinal motor mechanisms in hyperglycaemia induced delayed gastric emptying in type I diabetes mellitus. **Gut**, [s. l.], v. 40, n. 5, p. 641–6, 1997. Disponível em:

<<http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1027168&tool=pmcentrez&rendertype=abstract>>

SOGABE, M.; OKAHISA, T.; TSUJIGAMI, K.; OKITA, Y.; HAYASHI, H.; TANIKI, T.; HUKUNO, H.; NAKASONO, M.; MUGURUMA, N.; OKAMURA, S.; ITO, S. Ultrasonographic assessment of gastric motility in diabetic gastroparesis before and after attaining glycemic control. **Journal of Gastroenterology**, [s. l.], v. 40, n. 6, p. 583–590, 2005.

SPÅNGÉUS, A.; EL-SALHY, M.; SUHR, O.; ERIKSSON, J.; LITHNER, F.; EL-SALHY, M. Prevalence of Gastrointestinal Symptoms in Young and Middle-Aged Diabetic Patients Prevalence of Gastrointestinal Symptoms in Young and Middle-Aged Diabetic Patients. **Scandinavian Journal of Gastroenterology**, [s. l.], v. 3412, p. 1196–1202, 1999. Disponível em: <<http://www.tandfonline.com/action/journalInformation?journalCode=igas20> %5Cn<http://www.tandfonline.com/action/journalInformation?journalCode=igas20>>

WANG, X. Y.; HUIZINGA, J. D.; DIAMOND, J.; LIU, L. W. C. Loss of intramuscular and submuscular interstitial cells of Cajal and associated

enteric nerves is related to decreased gastric emptying in streptozotocin-induced diabetes. **Neurogastroenterology and Motility**, [s. l.], v. 21, n. 10, p. 1095–1107, 2009.

WATKINS, C. C.; SAWA, A.; JAFFREY, S.; BLACKSHAW, S.; BARROW, R. K.; SNYDER, S. H.; FERRIS, C. D. Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy. **Journal of Clinical Investigation**, [s. l.], v. 106, n. 3, p. 373–384, 2000.

WOERLE, H. J.; ALBRECHT, M.; LINKE, R.; ZSCHAU, S.; NEUMANN, C.; NICOLAUS, M.; GERICH, J. E.; GÖKE, B.; SCHIRRA, J. Impaired hyperglycemia-induced delay in gastric emptying in patients with type 1 diabetes deficient for islet amyloid polypeptide. **Diabetes Care**, [s. l.], v. 31, n. 12, p. 2325–2331, 2008.

WOOD, J. D. Enteric Nervous System: Neuropathic Gastrointestinal Motility. **Digestive Diseases and Sciences**, [s. l.], v. 61, n. 7, p. 1803–1816, 2016.

WU, T.; RAYNER, C. K.; YOUNG, R. L.; HOROWITZ, M. Gut motility and enteroendocrine secretion. **Current Opinion in Pharmacology**, [s. l.], v. 13, n. 6, p. 928–934, 2013. Disponível em:

<<http://www.sciencedirect.com/science/article/pii/S1471489213001628>>.

Acesso em: 7 jun. 2017.

ZHAO, J.; NAKAGUCHI, T.; GREGERSEN, H. Biomechanical and histomorphometric colon remodelling in STZ-Induced diabetic rats. **Digestive Diseases and Sciences**, [s. l.], v. 54, n. 8, p. 1636–1642, 2009.

Appendice

5. Apêndice A

Name of Journal: NEUROGASTROENTEROLOGY AND MOTILITY

Manuscript Type: ABSTRACT

Basic Study

Morphological changes and disorders in gastrointestinal motility in *Diabetes Mellitus*

J. Fernandes de Matos¹; M. F. Américo²; Y. K. Sinzato³; D. C. Damasceno³; M. Dal-Pai⁴; J. R. de Arruda Miranda¹

1 Paulista State University, Dept. of Biophysics, Botucatu, Brazil;

2 Institute Biological Sciences, Barra do Graças- MT, Brazil;

3 Medical School of Botucatu, Dept. gynecology, Brazil;

4 Paulista State University, Dept. Morphology, Botucatu, Brazil

Published online: November 30, 2018

Neurogastroenterology & Motility. 2018;30:30(Suppl. 1): e13443.

DOI: 10.1111/nmo.13443

JCR (2019): 3.842

FNM 2018 – 3rd Meeting of the Federation of Neurogastroenterology and Motility, which took place from 29 August to 1 September 2018 in Amsterdam, Netherlands.

Objective: The aim is to characterize the profile of gastric motility in rats with severe diabetes model and evaluate the influence of glycemic variations in TGI.

Methods: Biosusceptometry of Alternating Current (BAC) is a fairly simple technique, low cost and versatile in research related to the human TGI. BAC is composed of magnetic sensors based in inductions coil. An electrode was inserted for measurement of electrogastrography (EGG), and a ferrite bead to measure the BAC in the rats. Histological sections of the stomach were stained with hematoxylin and eosin, analyzed at a 10X magnification. Morphometry was performed to analyze the thickness of the muscular layers of the stomach. Severe diabetes was induced by a beta-cytotoxic agent (streptozotocin – 40 mg/kg, ip) at adult rats. They were evaluated contractility and gastric emptying of severe diabetic and control animals. $P < 0.05$ as statistical significance limit.

Results: There was a significant decrease in contraction frequency and increase in gastric emptying time of the diabetic animals compared with control. There was a thickening of the circular muscle and the mucosa layer of the stomach of diabetic animals. There is an influence of glycemic status on the GI tract and may have alterations of frequency and gastric emptying.

Conclusion: It is concluded that diabetes caused disorders in the gastric electrophysiology in the form of dysrhythmia, as well as delay in emptying and morphological changes.

Acknowledgement: FAPESP 2015/05045-8

Key Words: Diabetes, Stomach, AC Biosusceptometry

6. Apêndice B

Certificado de ética animal (CEUA 752)



UNIVERSIDADE ESTADUAL PAULISTA
"JÚLIO DE MESQUITA FILHO"
Campus de Botucatu




Certificado

Certificamos que o projeto intitulado “Caracterização da motilidade gastrointestinal em modelos experimentais de hiperglicemia”, Protocolo nº 752-CEUA, sob a responsabilidade de **José Ricardo de Arruda Miranda**, que envolve a produção, manutenção e/ou utilização de animais pertencentes ao filo Chordata, subfilo Vertebrata (exceto o homem), para fins de pesquisa científica (ou ensino) – encontra-se de acordo com os preceitos da Lei nº 11.794, de 9 de outubro de 2008, do Decreto nº 6.899, de 15 de julho de 2009, e com as normas editadas pelo Conselho Nacional de Controle da Experimentação Animal (CONCEA), e foi aprovado “Ad referendum” da **COMISSÃO DE ÉTICA NO USO DE ANIMAIS (CEUA)**, nesta data.

Vigência do Projeto:	Início: 01/11/2015	Término: 02/03/2019
Espécie/linhagem:	Rato Wistar	
Nº de animais:	50	
Peso:	250g	Idade: 90 dias
Sexo:	Macho	
Origem	Anilab Animais de Laboratório Criação e Comércio Ltda. – Paulínia/SP	

Botucatu, 6 de agosto de 2015.


Prof. Adj. Wellerson Rodrigo Scarano
Presidente da CEUA

Instituto de Biociências – Diretoria Técnica Acadêmica
Distrito de Rubião Júnior s/n CEP 18618-970 Botucatu SP Brasil
Tel 14 3880 0851 fax 14 3815 3744 e-mail: secda@ibb.unesp.br